New treatment options in allergic rhinitis: patient considerations and the role of ciclesonide

Abstract

Allergic rhinitis (AR) is a chronic inflammatory respiratory disease affecting 5%–50% of the worldwide population and its prevalence is increasing (Herman 2007). In addition, AR is associated with asthma and other co-morbidities such as conjunctivitis and sinusitis. The main symptoms are nasal congestion, rhinorrea, sneezing, itching, and post-nasal drainage induced after allergen exposure by an IgE-mediated inflammation of the membranes lining the nose. AR is not a life-threatening disease, but it has been shown to have a significant impact on quality of life. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines propose a classification of AR in intermittent and persistent, each graded as mild or moderate-severe, and provide a stepwise approach to the treatment. Inhaled steroids and antihistamine are the main tools in AR therapy but more safe and effective drugs are, however, needed. Inhaled steroid ciclesonide appears to be safe and effective.

Keywords:

• ciclesonide
• allergic rhinitis
• asthma
• quality of life

Acknowledgements

The authors thank ARMIA (Associazione Ricerca Malattie Immunologiche e Allergiche) for supporting the literature review. A special mention to Dr. Silvia Raco for the language revision.

Disclosures

The authors have no conflicts of interest to disclose.